Table 2.
Survival analyses on the ground-truth and NIC-classified HGP
| Desmoplastic versus non-desmoplastic | Non-desmoplastic 5-year OS (95% c.i.) | Desmoplastic 5-year OS (95% c.i.) | Desmoplastic versus non-desmoplastic | |
|---|---|---|---|---|
| Univariable HR (95% c.i.) | Multivariable HR (95% c.i.)* | |||
| Development cohort (n = 932) | ||||
| Ground-truth HGP | 40% (36,44) | 63% (57,70) | 0.57 (0.47,0.70) | 0.63 (0.50,0.79) |
| NIC-classified HGP | 40% (37,44) | 60% (54,67) | 0.61 (0.50,0.75) | 0.64 (0.51,0.79) |
| Validation cohort (n = 294) | ||||
| Ground-truth HGP | 64% (58,71) | 80% (70,91) | 0.51 (0.30,0.86) | 0.40 (0.22,0.75) |
| NIC-classified HGP | 66% (60,72) | 73% (63,84) | 0.64 (0.41,1.02) | 0.48 (0.28,0.83) |
*Corrected for age, sex, primary tumour location, pT-stage, pN-stage, disease-free interval, number of CRLM, diameter of largest CRLM, preoperative CEA, and extrahepatic disease. CEA, carcinoembryonic antigen; CRLM, colorectal liver metastasis; HGP, histopathological growth pattern; NIC, neural image compression; OS, overall survival.